Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Additive Anti-inflammatory Action for Critically Ill Patients With Cardiovascular Surgery (Xuebijing) IV

NCT04993794 is registered in ClinicalTrials.gov with Nanjing Medical University as lead sponsor.

NCT NCT04993794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04993794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Additive Anti-inflammatory Action for Critically Ill Patients With Cardiovascular Surgery (Xuebijing) IV
Lead sponsor
Nanjing Medical University
Phase
Not applicable
Overall status
Unknown status
Start date
January 1, 2021
Completion date
December 31, 2022
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aortic dissection, cardiovascular disease, congenital heart disease, coronary artery disease, critical illness, valve heart disease